Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: HerbVic who wrote (2499)	10/8/2001 6:52:05 PM
From: Savant	Read Replies (2) \| Respond to of 3576

Geron Corporation Presents at UBS Warburg Global Life Sciences Conference Business Editors/Health & Medical Writers MENLO PARK, Calif.--(BW HealthWire)-Oct. 8, 2001--Geron Corporation (Nasdaq:GERN) will be presenting a company overview on Wednesday, October 10, 2001, at the UBS Warburg Global Life Sciences Conference at 10:00 a.m. EDT. The presentation highlights the company's progress in all of its product development areas, including telomerase inhibition for the treatment of cancer and the differentiation of embryonic stem cells for the treatment of liver disease, Parkinson's disease and congestive heart failure. Geron's president and chief executive officer, Thomas B. Okarma, Ph.D., M.D., will be giving the presentation. To listen to the presentation in the U.S., please dial 1-800-500-0177; outside of the U.S., please dial 1-719-457-2679. Graphics for the presentation are located on Geron's website at www.geron.com. The replay of the presentation will be available for four weeks. To hear the replay in the U.S., please dial 1-800-759-8603; outside the U.S., please dial 1-402-220-8537. For further information, please contact Geron Corporation at 650-473-7765, visit Geron's website at www.geron.com or UBS Warburg's website at www.ubswarburg.com. Geron is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron's product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells and nuclear transfer. To receive an index and copies of recent press releases, call Geron's News On Demand toll-free fax service, 1-800-782-3279. --30--pw/sf* CONTACT: Geron Corporation Olivia Bloom, 650/473-7765 (Investor and Media Relations) or Burns McClellan, Inc. Nancy Robinson, 650/352-6262 (Investor Relations) KEYWORD: CALIFORNIA INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL SOURCE: Geron Corporation ======== Herb, you didn't play fair..OUT of the sandbox..LOL